

INNOVATION VENTURES

AVAILABLE TECHNOLOGIES

CONTACT US

Request Information

Permalink

Novel Cell Therapy for CTLA4 Haploinsufficiency

Tech ID: 33012 / UC Case 2021-282-0

INVENTION NOVELTY

Scientists have developed a CRISPR-Cas9 based genome editing method for universal correction of disease-causing mutations in the CTLA4 gene, which most commonly manifest as a Primary Immunodeficiency. Current treatment involves monthly IV injections or weekly subcutaneous injections of a recombinant CTLA4-Ig fusion protein abatacept. This invention includes one-time infusion of a CTLA4-corrected autologous T cell therapy. The corrected patient cells are generated by ex vivo electroporation of a specific gRNA:Cas9 ribonucleoprotien (RNP) complex and cognate homology-directed-repair template (HDRT) targeting a functional copy of the CTLA4 gene within an intronic region of the endogenous CTLA4 gene. This combination allows for (1) highly efficient knockin (up to 70% in patient cells), (2) cell-type and context specific regulation of CTLA4 expression under natural promoter and regulatory elements, and (3) preservation of endogenous CTLA4 expression in uncorrected cells.

VALUE PROPOSITION

- Universal open reading frame replacement strategy can be applied to the vast majority of known CTLA4 mutations.
- Intronic targeting approach prevents loss of CTLA4 in targeted cells to enhance product safety and activity.
- Fully non-viral engineering methods reduce manufacturing cost and complexity.
- Strategies can be applied to a wide variety of alternative inherited immune disorders.

RELATED MATERIALS

► High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails - 08/25/2022

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney
Gemma.Rooney@ucsf.edu
tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

CTLA4 haploinsufficiency,

Primary Immunodeficiency,

Non-viral gene editing,

CRISPR-Cas9, CTLA4,

Autologous T cell therapy

CATEGORIZED AS

- **▶** Medical
 - Disease:

Autoimmune and

Inflammation

- Gene Therapy
- Therapeutics

RELATED CASES

2021-282-0

CONNECT

UCSFinnovation@ucsf.eduInnovation Ventureshttps://innovation.ucsf.edu© 2022, The Regents of the University of600 16th St, Genentech Hall, S-272,Fax:California

Terms of use Privacy Notice

San Francisco,CA 94158